header logo image


Page 794«..1020..793794795796..800810..»

Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. – DocWire…

December 13th, 2019 8:50 pm

This article was originally published here

Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts.

F1000Res. 2019;8:1194

Authors: Camargo JF, Ahmed AA, Lindner MS, Morris MI, Anjan S, Anderson AD, Prado CE, Dalai SC, Martinez OV, Komanduri KV

AbstractBackground: Cell-free DNA (cfDNA) sequencing has emerged as an effective laboratory method for rapid and noninvasive diagnosis in prenatal screening testing, organ transplant rejection screening, and oncology liquid biopsies but clinical experience for use of this technology in diagnostic evaluation of infections in immunocompromised hosts is limited. Methods: We conducted an exploratory study using next-generation sequencing (NGS) for detection of microbial cfDNA in a cohort of ten immunocompromised patients with febrile neutropenia, pneumonia or intra-abdominal infection. Results: Pathogen identification by cfDNA NGS demonstrated positive agreement with conventional diagnostic laboratory methods in 7 (70%) cases, including patients with proven/probable invasive aspergillosis, Pneumocystis jirovecii pneumonia, Stenotrophomonas maltophilia bacteremia, Cytomegalovirus and Adenovirus viremia. NGS results were discordant in 3 (30%) cases including two patients with culture negative sepsis who had undergone hematopoietic stem cell transplant in whom cfDNA testing identified the etiological agent of sepsis; and one kidney transplant recipient with invasive aspergillosis who had received >6 months of antifungal therapy prior to NGS testing. Conclusion: These observations support the clinical utility of measurement of microbial cfDNA sequencing from peripheral blood for rapid noninvasive diagnosis of infections in immunocompromised hosts. Larger studies are needed.

PMID: 31814964 [PubMed in process]

Continued here:
Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. - DocWire...

Read More...

Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium – GlobeNewswire

December 13th, 2019 8:50 pm

FLORHAM PARK, N.J., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod Longcor, chief business officer of Cellectar, presented a poster at the AACR San Antonio Breast Cancer Symposium in San Antonio, TX.

The poster, entitled: Preclinical evaluation of a novel phospholipid drug conjugate, CLR 2000045 with a combretastatin A-4 analogue for improved breast cancer therapy, featured data demonstrating potent in vivo activity in multiple animal models of breast cancer, including a model of triple negative breast cancer. Multiple doses of CLR 2000045 resulted in a statistically significant reduction in tumor volume (p<0.05 and 0.01 respectively) and survival (p<0.05 and 0.001 respectively) in the HCC70, triple negative breast cancer model as compared to vehicle control. In a separate study, the compound displayed comparable activity to paclitaxel in an initial screening model of metastatic breast cancer and the data showed that all doses of CLR 2000045 were well tolerated in both models.

The data further demonstrate that PDCs are an exciting and novel class of targeted oncology agents with potential in a wide variety of tumor types, said Jarrod Longcor, chief business officer of Cellectar. We have validated targeted delivery to tumor cells and shown efficacy in multiple cancer types utilizing our phospholipid ether delivery vehicle with four separate classes of molecules. These data demonstrate the unique potential of our novel cancer targeting platform.

About Phospholipid Drug Conjugates

Cellectar's product candidates are built upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates (PDCs) to target cancer cells. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors. This selective delivery allows the payloads therapeutic window to be modified, which may maintain or enhance drug potency while reducing the number and severity of adverse events. This platform takes advantage of a metabolic pathway utilized by all tumor cell types in all cell cycle stages. Compared with other targeted delivery platforms, the PDC platforms mechanism of entry does not rely upon specific cell surface epitopes or antigens. In addition, PDCs can be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively delivered. Cellectar believes the PDC platform holds potential for the discovery and development of the next generation of cancer-targeting agents.

About Cellectar Biosciences, Inc.Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development (R&D) collaborations. The companys core objective is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The companys PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The companys lead PDC therapeutic, CLR 131, is currently in three clinical studies a Phase 2 study, and two Phase 1 studies. The Phase 2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphoma.

The companys product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900) and several partnered PDC assets.

For more information, please visit http://www.cellectar.com or join the conversation by liking and following us on our social media channels: Twitter, LinkedIn, and Facebook.

Forward-Looking Statement Disclaimer

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may", "expect", "believe", "anticipate", "intend", "could", "estimate", "continue", "plans", or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of CLR 131, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2018 and Form 10-Q for the quarters ended March 31, 2019, June 30, 2019 and September 30, 2019. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

Contacts

Investors: Monique KosseManaging DirectorLifeSci Advisors212-915-3820monique@lifesciadvisors.com

Follow this link:
Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium - GlobeNewswire

Read More...

Stem Cell Therapy for Osteoarthritis Market Growth Scope Assessment 2019: Regeneus, Mesoblast, Asterias Biotherapeutics – Global Industry Analysis

December 13th, 2019 8:50 pm

The Global Stem Cell Therapy for Osteoarthritis market report 2019-2026 provides basic and elementary information about the universal industry. The study report on the Stem Cell Therapy for Osteoarthritis market has been designed using a set of principal as well as subordinate methods which are accountable to offer accurate and meticulous information with respect to the Stem Cell Therapy for Osteoarthritis market dynamics, the recent industry landscape, and historical achievements. In addition to this, the Stem Cell Therapy for Osteoarthritis market report contains a detailed SWOT analysis of the overall Stem Cell Therapy for Osteoarthritis industry.

The worldwide Stem Cell Therapy for Osteoarthritis market report unfolds the industrial data and the projection of the Stem Cell Therapy for Osteoarthritis market on a regional basis. Furthermore, the Stem Cell Therapy for Osteoarthritis market report establishes various subjective as well as quantitative evaluation by industry experts, analysts and executives through a detailed Stem Cell Therapy for Osteoarthritis market worth chain. Thus, this report is an extremely beneficial resource for all the readers and new participants who are interested in this market.

Access the Sample Copy of the report @ https://marketresearchexpertz.com/report/global-stem-cell-therapy-osteoarthritis-market-37628#request-sample

Additionally, the global Stem Cell Therapy for Osteoarthritis market report delivers a brief investigation of ever-changing business sector aspects, patterns, restraints and drivers in the Stem Cell Therapy for Osteoarthritis industry. All these elements are considered as a crucial part in the global industry and meanwhile, it highlights the standard industrial structure of the world Stem Cell Therapy for Osteoarthritis market along with positive and negative viewpoints. A detailed assessment of the Stem Cell Therapy for Osteoarthritis market size, revenue, production, deals, Stem Cell Therapy for Osteoarthritis market share is also discussed in the Stem Cell Therapy for Osteoarthritis market research report.

Remarkable Players covered in this report are:MesoblastRegeneusU.S. Stem CellAnterogenAsterias BiotherapeuticsOther

Stem Cell Therapy for Osteoarthritis Market Segregation based on Types:MonotherapyCombination Therapy

The Application can be Segmented as:Osteoarthritis (unspecified)Knee OsteoarthritisShoulder OsteoarthritisHip Osteoarthritis

Inquiry Before Buying A Report Here: https://marketresearchexpertz.com/report/global-stem-cell-therapy-osteoarthritis-market-37628#inquiry-for-buying

Stem Cell Therapy for Osteoarthritis Market Segment by Regional Analysis:

North America Europe Asia-Pacific Latin America Middle East & Africa

Reportedly, the newly published report on the global Stem Cell Therapy for Osteoarthritis market includes all the necessary aspects including new product launches, major strategical developments of the Stem Cell Therapy for Osteoarthritis market, agreements, joint ventures, collaborations and region-wise growth of the top competitors operating in the Stem Cell Therapy for Osteoarthritis market based on the regional and worldwide scale.

Browse More Details With TOC: https://marketresearchexpertz.com/report/global-stem-cell-therapy-osteoarthritis-market-37628

The worldwide Stem Cell Therapy for Osteoarthritis market also elaborates capacity, revenue, gross margin, utilization rates, consumption, production rate, import as well as export data, supply or demand ratio, price, Stem Cell Therapy for Osteoarthritis market share, cost, CAGR and much more. Besides this, the Stem Cell Therapy for Osteoarthritis market report covers a comprehensive analysis of the vital Stem Cell Therapy for Osteoarthritis market dynamics and meanwhile, their recent trends alongside pertinent industry segments as well as sub-segments.

Continue reading here:
Stem Cell Therapy for Osteoarthritis Market Growth Scope Assessment 2019: Regeneus, Mesoblast, Asterias Biotherapeutics - Global Industry Analysis

Read More...

Interview with Gavin Jeffries from Fluicell: Cell Biology is at the Core of our Work – 3DPrint.com

December 13th, 2019 8:50 pm

Getting to know cells well helps understand how organisms function. This is one of the aspects that drive scientists, researchers, and physicians to create bioprinting technology to generate living structures that can mimic the actual environment of human tissues. Bioprinters today usually involve a syringe-like mechanism to deposit cell material within a gel or scaffold structure, which helps keep the desired 3D shape while printing and is then washed away or dissolved. A Swedish company called Fluicell is out to change the reigning trend and has just released a new system for cell 3D printing. Based on innovative open-volume microfluidics technology, their brand new bioprinting system, Biopixlar, is capable of generating detailed, multi-cellular biological tissues without the need for a gel matrix.

The Biopixlar bioprinter

Biopixlar is designed for handling scarce and valuable cell sources such as stem cells, primary cells, and patient biopsies. The company has actually begun working at their own labs building full tissue and cancer models, which usually takes them just 24 hours to print thanks to their technology. The system is an all-in-one discovery platform that allows the printing of multiple types of different cells at once with high precision and resolution. One of the fun features is the gamepad interface, used to manually control the position of the print head and deposit the cells. Also, an integrated multi-color fluorescence imaging configuration enables real-time monitoring of the printing process and post-print analysis.

Gavin Jeffries

Fluicell, a spin-off company out of Chalmers University of Technology, in Sweden, has been around since 2012, developing biotech hardware devicesincluding the BioPen and Dynaflow Resolve systemsbut their research has taken them to explore changes in the bioprinting market, namely producing human-like tissue replicas. 3DPrint.com spoke to Gavin Jeffries, co-founder and Chief Technology Officer at Fluicell, to understand the process behind Biopixlar.

How did Fluicell become a pioneer in open-volume microfluidics?

Microfluidics is essentially the control of liquids on a smaller scale and is very useful when scientists need to handle the smallest amounts of liquid or have very rare samples and need fast responses. Over the last 20 years, microfluidics has been advancing quite a lot but has largely focused on chip-based devices, which means the whole field is centered around putting cells or liquids inside another device. When we first started the company we noticed that having something inside a device was restrictive, because within biology you normally want to have your cells in a petri dish or on your microscope, not inside a chip. But at the same time, we wanted to harness the power of microfluidics to use small sample amounts and have those very fast response times, so essentially we came up with a way of very precisely controlling both positive and negative pressures to allow control of liquids outside of our microfluidic chip. Meaning we can still have the function of microfluidics but in an open volume (basically in any kind of biological platform.) Since 2011, this technology has been picked up by different fields for research.

How will the gamepad simplify the user experience?

Biopixlar is a complete discovery platform, with everything embedded in it. Actually, just like a game system, the gamepad interface provides user control over the responsivity of the machine. This control format is ideal for people who are coming into the workforce and who have grown up with advanced interfaces, without the need to use a mouse or a keyboard. We also hoped to focus on the comfort of working with the device, for example, researchers will be able to get a direct response in real-time because it is fully embedded with microscopy, so they will see everything they are doing, every cell they put in, just everything.

Biopixlar is designed to be a complete platform where discovery science is its home and marketplace. Research and development, whether it is looking at disease models or interrogating biological systems, the user has control over building these early-stage models as accurately as possible. These can be found in academia and the pharma industry, so it will be our first bridge between the two market segments.

Closeup of the Biopixlar printhead

What makes Biopixlar so unique?

After one layer of cells is put down, Biopixlar allows them to grow and then pattern them using a molecular cell binder to put the next level of cells, and so on, building up layer by layer and using the extracellular matrix binding agent in between, which would naturally be reproduced by the cells. We chose to use components of the extracellular matrix that are naturally formed with the cells so that the device can pattern them on top of the cells which are printed, allowing for more cells to attach. In this way, researchers will not need to house the cells in any binder to build in three dimensions.

Why is cell viability really high with the Biopixlar system?

That is largely because of the microfluidics within the device. We use a consumable cartridge to load the cells, but inside there is a series of complex circuitry that allows the handling of liquids in a no-sharing regime so the fluids dont rub against each other and the cells are much happier being in this kind of no shared environment. When we patterned the cells at the lab, we noticed that there is no negative impact of printed cells versus putting them in a dish. Moreover, we feel comfortable and very happy that we minimally interfere with the cells when we build them into the structure that we want to create.

Printed skin cancer model

Do you consider Biopixlar will be successful among researchers?

We stand alone within the market of bioprinting because we do not need to use any binding matrix, our goal is to put cells as close as possible to each other so that they begin communicating straight away. Most of the full tissue and cancer models we built at the lab were done within 24 hours, and this is largely due to the fact that we dont have anything in the way of the cells communicating with each other. Additionally, thanks to the gamepad, we can see exactly what we are doing in real-time. The technology sparks interest in the field because people can actually see the bridge between advanced technology and biology and we are now starting to get to a point where we can show results and people are starting to get excited about them.

Is understanding cell behavior at the core of what you do?

The only thing which we are really focusing on is the cells. With Biopixlar, scientists dont have to pattern ink or deposition areas, they will not have to deal with that and instead, focus on the cells. Biopixlar has a unique advantage to see if anything is going wrong because if something were to happen to the cells or the biology during the process, it will be seen directly. Thanks to the high-resolution microscopy, we can interrogate the cells as they are printed or while they are growing. This all-in-one discovery platform approach is necessary to carry out bioprinting while providing advantages over how the biological tissues are actually built.

Printed liver cancer model

How would you describe Biopixlar to a potential buyer?

It is a high-resolution machine that fits in a comfortable lab setting with an easy-to-use experience, built with microscopy for looking at individual cells. Researchers need an accurate micro position to move around all the microcomponents while having a very stable infrastructure because it is moving on the micron size scale, instead of the millimeter size, we wouldnt want it to vibrate and lose calibration in the middle of a print. Overall, it is an accessible, original and optimal resolution device for lab spaces.

Originally posted here:
Interview with Gavin Jeffries from Fluicell: Cell Biology is at the Core of our Work - 3DPrint.com

Read More...

Iran ready for full prisoner swap, ‘ball is in the US’ court’: Zarif – CNA

December 13th, 2019 8:49 pm

DUBAI: Foreign Minister Mohammad Javad Zarif said on Monday (Dec 9)Iran is ready for a full prisoner exchange with the United States, tweeting: "The ball is in the US court".

"After getting our hostage back this week, fully ready for comprehensive prisoner exchange," Zarif said.

The United States and Iran on Saturday swapped prisoners - American graduate student Xiyue Wang, detained for three years on spying charges, and imprisoned Iranian stem-cell researcher Massoud Soleimani, accused of sanction violations - in a rare act of cooperation between two longtime foes.

Separately, Iranian government spokesman Ali Rabiei said Iran had always sought an "all for all release" with the United States.

"We are ready to cooperate to return all Iranians who are being held unjustly in America," Rabiei was quoted by the state news agency IRNA as saying.

Rabiei said efforts to swap prisoners were not linked to any other US-Iranian talks, which would only be possible if Washington lifted sanctions and returned to Tehran's 2015 nuclear deal with world powers.

Tensions have heightened between Iran and the United States since USPresident Donald Trump last year pulled Washington out of the nuclear deal and reimposed sanctions that have crippled Tehran's economy. Iran has responded by gradually scaling back its commitments under the agreement.

Washington has demanded that Iran release the Americans it is holding, including father and son Siamak and Baquer Namazi; Michael R. White, a Navy veteran imprisoned last year; and Robert Levinson, a former FBI agent missing since 2007.

Several dozen Iranians are being held in USprisons, many of them for breaking sanctions.

See original here:
Iran ready for full prisoner swap, 'ball is in the US' court': Zarif - CNA

Read More...

Politics this week – The Economist

December 13th, 2019 8:49 pm

Dec 14th 2019

The Conservative Party won an emphatic victory in Britain's general election. With most of the seats counted, the Tories were set to have a majority of well over 70. It was a personal triumph for the prime minister, Boris Johnson, who can now "get Brexit done"--and a lot more besides. Labour had its worst result since 1935.

The House of Representatives presented two articles of impeachment against Donald Trump: that the president abused his power by pressing Ukraine to dig up dirt on Joe Biden, and that he obstructed Congress by insisting that key witnesses cannot testify. The votes on those charges are expected to be swift and along party lines in the House. Mr Trump could be impeached before Christmas, setting up a trial early next year in the Senate, which will in all likelihood acquit him. See article.

Officials in Jersey City, which lies across the Hudson river from Manhattan, said three people murdered in a kosher market may have been targeted for anti-Semitic reasons. The two shooters, linked to a black hate group that considers itself the true Israelites, also killed a policeman before entering the store. The suspects were killed during an hours-long gun battle with police.

A trainee in the Saudi air force murdered three sailors at a navy training base in Pensacola, Florida, before being shot dead by police. The motive was unclear but terrorism is one line of inquiry. See article.

Alberto Fernndez, a Peronist, took office as Argentinas president. The economy he inherits from his centre-right predecessor, Mauricio Macri, is in recession and has an inflation rate of more than 50%. In his inauguration address Mr Fernndez promised to end the social catastrophe of hunger and said Argentina could not pay its foreign creditors unless its economy grows. See article.

Genaro Garca Luna, who was Mexicos secretary of public security during the presidency of Felipe Caldern, was arrested in Texas. Prosecutors say he took millions of dollars in cash from the Sinaloa drug gang in exchange for protecting its activities and providing intelligence to it. Mr Caldern, who was president from 2006 to 2012, waged a bloody war against Mexicos drug gangs.

Hondurass congress voted to recommend that the president not renew the mandate of MACCIH, a corruption-fighting mission backed by the Organisation of American States. Lawmakers complained that it disclosed names of people under investigation, but most Hondurans back MACCIH, which helped to jail a former first lady.

None of Israels political parties was able to form a government before the December 12th deadline, so the country will hold another election, its third in less than a year, on March 2nd. Polls show little change in voter preferences.

America and Iran exchanged prisoners in a rare bit of diplomacy between the two countries. The swap involved a Chinese-American researcher who had been convicted of spying in Iran, and an Iranian stem-cell scientist who was held by America for trying to export biological material.

Opposition activists claimed that up to 1m people took to the streets in Conakry, the capital of Guinea, to protest against the rule of President Alpha Cond. Mr Cond is meant to step down at the end of his second term next year, but he may try to change the constitution so that he can run for a third term.

Militants killed 73 soldiers in an army base in western Niger. The attack, the deadliest in years, highlights the rapidly deteriorating security situation across the Sahel.

Security forces in Nigeria seized Omoyele Sowore, a journalist and activist, while he was appearing in court the day after judges had forced the state to release him. Mr Sowore, who had been held since August, has been charged with treason after criticising President Muhammadu Buhari and calling for civil unrest.

Indias parliament passed a law offering a fast track to citizenship to minorities who face persecution in Afghanistan, Bangladesh and Pakistan, as long as they arent Muslim. The new law applies to Hindus, Sikhs, Buddhists, Christians and others. Muslims condemned it as an attempt by Indias Hindu-nationalist government to marginalise them. The law has been appealed to the Supreme Court. See article

Aung San Suu Kyi defended Myanmar against charges of genocide at the International Court of Justice in The Hague. The Nobel peace-prize winner described the Myanmarese armys bloody crackdown on Rohingya Muslims in 2017, in which thousands were killed or raped and 700,000 fled to Bangladesh, as an internal conflict started by Rohingya militants. See article.

Police in Malaysia said they would interview Anwar Ibrahim, the countrys prime-minister-in-waiting, about an allegation that he sexually assaulted a male aide. As leader of the opposition in 1999 Mr Anwar was imprisoned on trumped-up charges of sodomy, which is illegal in Malaysia. He dismissed the allegation as political.

Voters in Bougainville, an autonomous region of Papua New Guinea, voted by 98% to 2% for independence. Bougainville has long had a distinct identity; 15,000-20,000 people were killed in a civil war that was fuelled by separatist grievances and ended in 1998. The referendum, however, is non-binding.

Hundreds of thousands of people marched through Hong Kong in the citys first authorised protest since August and the largest in weeks. The demonstration, organised to mark the UNs human-rights day, was mostly peaceful. Afterwards, however, some protesters threw firebombs at official buildings.

A Chinese official, Shohrat Zakir, said everyone had graduated from vocational education and training camps in Xinjiang. An estimated 1m people, most of them ethnic-Uighurs, have been detained in what are in fact prison camps, often just for being devout Muslims. Mr Zakir said training would continue at the camps, with the freedom to come and go. Independent witnesses were not allowed in to verify his claims. See article.

Frances prime minister unveiled details of the governments plan for pension reforms, which put some of the toughest changes off into the future. But this may not be enough to halt a wave of strikes that have shut down most of the rail network, many schools and the Paris Mtro. See article.

A new government was sworn in in Finland. All five of the parties in the new ruling coalition are led by women. See article.

Russia was banned from major sporting competitions for a period of four years, which will cover next years Olympics, after revelations that it had hacked and faked medical records dealing with doping. The ban contains significant loopholes, however. See article.

This article appeared in the The world this week section of the print edition under the headline "Politics this week"

Go here to see the original:
Politics this week - The Economist

Read More...

Stem Cell Cartilage Regeneration Market 2025: Topmost manufacturers With Size, Regions, Types, Major Drivers, Profits – UPNewsIndustry

December 13th, 2019 8:49 pm

The industrial research report on Global Stem Cell Cartilage Regeneration market growth 2019-2024 published by MarketReports.co, the global and Chinese researchers are in-depth study on the present place of the Stem Cell Cartilage Regeneration organizations with main focus on the Chinese market.

The report examines the major things countable for driving the growth of Stem Cell Cartilage Regeneration market 2019-2024, various factors like economic stability, lifting population, rapidly enhancing demand, developments and geographic regions, etc.

Sample report can be viewed in a PDF form by visiting @ marketreports.co/global-stem-cell-cartilage-regeneration-market-research-report-2019-2025/164768/#Free-Sample-Report

The reports prophesy growth at a global regional level and country level and provide the analysis of the market trends from 2019-2024, industrial development is show in term of revenue of the few regions like UN, GCC nations, Europe, Canada

After buying this report you will be aware of common business methodologies used by leading challengers of the global market researchers taken into production site, market share, and SWOT analysis key methodologies are covered.

The global Stem Cell Cartilage Regeneration market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

Stem Cell Cartilage Regeneration Market Segment by Manufacturers include:

Stem Cell Cartilage Regeneration Market Segment by Regions includes:

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America, Middle East and Africa

By Types, the Stem Cell Cartilage Regeneration Market can be Split into:

Cell Based Approaches

Non-cell Based Approaches

By Applications, the Stem Cell Cartilage Regeneration Market can be Split into:

Read Detailed Index of full Research Study at @ marketreports.co/global-stem-cell-cartilage-regeneration-market-research-report-2019-2025/164768/

Key growth prospect:

Browse Detailed TOC, Tables, Figures, Charts And Companies Mentioned In Stem Cell Cartilage Regeneration Market Research Report [emailprotected] marketreports.co/global-stem-cell-cartilage-regeneration-market-research-report-2019-2025/164768/#Buying-Enquiry

Request customized copy of Stem Cell Cartilage Regeneration report:

If you wish to find more details of the report or want customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us: [emailprotected]

View original post here:
Stem Cell Cartilage Regeneration Market 2025: Topmost manufacturers With Size, Regions, Types, Major Drivers, Profits - UPNewsIndustry

Read More...

Global Cancer Stem Cells Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – E-Industry News

December 13th, 2019 8:49 pm

The Cancer Stem Cells Market report gives an astonishing source to analyze the Cancer Stem Cells market and other fundamental subtleties identifying with it. The examination uncovers the general evaluation and associated ideas of the Cancer Stem Cells market. The report displays a reasonable scenario of the Cancer Stem Cells market, that links applications, proposals, industry chain structure, and definitions. Likewise, it connects the expansive validity of the Cancer Stem Cells market and configurations to a fundamental precision, experiences, and industry-substantiated estimations of the general Cancer Stem Cells market. Additionally, the examination underlines the huge driving business players (Thermo Fisher Scientific, Abbvie, Merck Kgaa, Bionomics, Lonza, Stemline Therapeutics, Miltenyi Biotec, Promocell, Macrogenics, Oncomed Pharmaceuticals, Irvine Scientific, Stemcell Technologies, Sino Biological, Biotime) across the globe with clear affiliation profiles, data of the wide-ranging business, item type, conditions, and courses of action.

The Cancer Stem Cells market report more focuses on top industry leaders and explores all essentials facets of competitive landscape. It explains potent business strategies and approaches, consumption propensity, regulatory policies, recent moves taken by competitors, as well as potential investment opportunities and market threats also. The report emphasis crucial financial details of major manufacturers including year-wise sale, revenue growth, CAGR, production cost analysis, and value chain structure.

Interesting? Apply for a sample report: http://www.intenseresearch.com/market-analysis/global-cancer-stem-cells-market-2018-by-manufacturers.html#request-sample

The manufacturing base, Cancer Stem Cells Industry chain view, raw material cost, labor cost, and downstream buyers analysis is represented. The production and market share by type and application from 2019-2025 are presented in this study. Also, the consumption ratio, gross margin analysis, and import-export statistics are portrayed. The market status and SWOT analysis for different regions and countries are profiled in this report.

Global Cancer Stem Cells Market: Type Outlook:Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis, Others

Global Cancer Stem Cells Market: Application Outlook:Breast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment, Lung Cancer Diagnosis and Treatment, Others

North America (United States, Canada)Europe (Germany, France, UK, Italy, Russia, Spain)Asia Pacific (China, Japan, Korea, India, Australia, New Zealand)Middle East & Africa (Middle East, Africa)Latin America (Mexico, Brazil, C. America, Chile, Peru, Colombia)

Furthermore, the report provides the core knowledge of the market by analyzing end users consumption tendency, Cancer Stem Cells market driving factors, ever-changing market dynamics, and rising development patterns in the market.

Besides, the report focuses on the leading contenders in the Cancer Stem Cells industry and delivers an all-inclusive analysis considering their market share, production capacity, value chain analysis, size, sales and distribution network, import/export activities, cost structure, and product specification. Due to the changes in world business policies, it is recommended to be always aware of the facts and data about this market.

The study objectives of this report are:

1) To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).2) To understand the structure of the Cancer Stem Cells market by identifying its various sub-segments.3) The marketing strategies, opportunities, and Cancer Stem Cells development factors are explained.4) The competitive landscape structure, market size estimation, recent advancements in the industry are explained.5) The market dynamics, competition, and complete insights will lead to profitable business plans.6) The pricing structure covering the labor cost, raw material cost, capacity, and supply-demand statistics are presented.

The key dynamic factors that are detailed in the report:

Key Market Dynamics: The Global Cancer Stem Cells Market research report details the latest industry trends, growth patterns, and research methodologies. The factors that directly contribute to the growth of the market include the production strategies and methodologies, development platforms, and the product model itself, wherein a small change would result in further changes in the overall report. All of these factors are explained in detail in the research study.

Market Outlook: The report also sheds light on some of the major factors, including R&D, new product launches, M&A, agreements, partnerships, joint ventures, collaborations, and growth of the key industry participants, on a regional and global basis.

Major Features: The report provides a thorough analysis of some of the significant factors, which include cost, capacity, capacity utilization rate, production, revenue, production rate, consumption, import/export, supply/demand, gross, market share, CAGR, and gross margin. Besides, the report provides a comprehensive study of the key influencing factors and market inclinations, in addition to the relevant market segments and sub-segments.

Analytical Tools: The Global Cancer Stem Cells Market report consists of the precisely studied and evaluated information of the key players and their market scope using several analytical tools, including SWOT analysis, Porters five forces analysis, investment return analysis, and feasibility study. These tools have been used to efficiently study the growth of major industry participants.

Potential Customers: The report offers detailed insights to users, service providers, suppliers, manufacturers, stockholders, and individuals who are interested in evaluating and self-studying this market.

Inquiry for Buying Report: http://www.intenseresearch.com/market-analysis/global-cancer-stem-cells-market-2018-by-manufacturers.html#inquiry-for-buying

Conclusively, the report helps a reader to get an absolute understanding of the Cancer Stem Cells industry through details about the market projection, competitive scenario, industry environment, growth constraining factors, limitations, entry barriers, the provincial regulatory framework as well as upcoming market investment and opportunities, challenges and other growth-promoting factors. This report will provide you a clear view of each and every facet of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read more from the original source:
Global Cancer Stem Cells Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - E-Industry News

Read More...

Famous Foxes Bred for Tameness Werent Actually Wild in the First Place, Claims Controversial New Paper – Gizmodo

December 13th, 2019 8:49 pm

A domesticated fox in Russia.Photo: Getty Images

Decades ago, a Soviet geneticist purposely bred foxes to make them extra tame, an experiment that produced a host of unanticipated physical changes in the animals. Its one of the most famous experiments in genetics, but it might not have gone down in the way we were told. A new opinion paper argues these foxes werent wild to begin with and that the domestication syndrome associated with the changes doesnt exista claim thats stirring up controversy among some biologists.

As the story goes, geneticist Dimitry Belyaev, who worked at the Institute of Cytology and Genetics in Novosibirsk, USSR, took 30 male and 100 female wild foxes (Vulpes vulpes), and, over the course of the next few decades, bred only the most human-friendly individuals. The experiment began in 1959, and by the late 1970s10 generations laterBelyaevs foxes were exhibiting the desired behavior, showing affection toward humans in a manner eerily reminiscent of dogs.

At the same time, however, the foxes acquired a host of unanticipated and unintended physical characteristics that distinguished them from the source population, such as floppy ears, turned-up tails, piebald coats, and wider faces, among other traits.

None of these physical characteristics were selected for, but Belyaev believed these traits were tied to the selected behavioral change (i.e. tameness), which somehow influenced the rise of unexpected traits. The Russian Farm-Fox Experiment, as its now called, has since been used by biologists to showcase the sweeping influence of domestication on a species. It also invigorated a term used to describe the phenomenon: domestication syndrome, as these sorts of physical changes have been documented in other domesticated animals, such as dogs, horses, and cows.

But as a new opinion paper published in Trends in Ecology & Evolution points out, a critical part of this story isnt actually true: the original foxes used in the experiment werent actually taken from the wild. Moreover, and perhaps more controversially, the authors, who include Elinor Karlsson, a biologist from the University of Massachusetts Medical School, and Gregor Larson, a paleogeneticist from the University of Oxford, contend that domestication syndrome is a half-baked concept thats probably not even a real condition.

That Belyaevs foxes werent originally wild seems to be the case. The authors provided evidencemuch of it already publicly availableshowing that Belyaev acquired the foxes from Soviet fur farms, which in turn had acquired their foxes from Canadian breeders, specifically fox farms in Prince Edward Island. Canadian entrepreneurs had been domesticating foxes since the late 19th century, selecting for both appearance and behavior, according to the paper. So by the time Belyaev got his hands on them, these foxes were already going through domestication.

And in fact, Belyaev himself admitted as much, describing the founding population as fur-farm foxes, but because he referred to them as wild controls, he unintentionally created a misconception.

The story wed heard was that the Russian scientists had started with a wild population of foxes, selectively bred the least fearful foxes, and as a result of that selection, also gotten foxes with white spots, curly tails, and other changes, Karlsson told Gizmodo. But up in Canada, they had foxes that were not fearful and already had white spotting (we dont know about curly tails)decades before the project started. And then we found the fox project in Russia didnt start with wild foxes, but with fur farm foxes originally from Canada. It totally changes the way I think about cause and effect in the project, she said.

Karlsson said her team concluded that Belyaev was continuing a domestication process that had already started many decades earlier in Canada.

Were not saying they are indistinguishable, said Karlsson of Belyaevs later generations of foxes and the founding group from the Soviet fur farms. But she said her team doesnt think that any of the changes since the Russian project started would suddenly qualify the foxes as now being domesticated.

Its entirely possible, she said, that Belyaev created even more friendly foxes, but even before this experiment began, we know the foxes were already okay being around humansand some of them were pretty happy about it, at least according to the photos and storiesand were breeding in captivity, which are the essential elements that are used to qualify them as being domesticated.

But the larger issue described in the paper is that there isnt really any good definition for domestication, Karlsson said, which made this hard to write about!

Karlsson and her colleagues argue against the existence of a so-called domestication syndrome, which they define as a suite of behavioral and morphological characteristics consistently observed in domesticated populations. The term was coined by botanists in the early 20th century, but Charles Darwin hinted at its existence in his 1868 book, The Variation of Animals and Plants Under Domestication. It was eventually applied to mammals in the 1980s, and its usage has risen dramatically since the 1990s, according to the new research.

Upturning the concept is a big deal, because domestication syndrome has inspired many related ideas, including the neural crest hypothesis and the pedomorphosis hypothesis. The neural crest hypothesis suggests neural crest cellsa specific class of stem cellsare a common factor in influencing the biological cascade that leads to multiple unanticipated physical changes in a species. The pedomorphosis hypothesis, also known as neoteny, suggests some of the changes introduced by domestication have a distinct juvenile quality and that selecting for tameness and other attributes effectively maintains a species, or at least some of its attributes, at an underdeveloped level. (In fact, some scientists argue that humans have tended to select mates with more juvenile features, leading to the hypothesis that humans exhibit certain features consistent with self-domestication.)

The authors looked to various domesticated mammalian species in order to further scrutinize the concept of domestication syndrome. In addition to domesticated foxes, the authors examined the characteristics of other species of domesticated animals, including dogs, cats, goats, pigs, rabbits, rats, and mice. The researchers charted their anomalous traits, such as shorter jaws, curled tails, drooping ears, changes in coat color and patterning, earlier sexual maturation, decreased brain size, and other attributes typically associated with domestication syndrome. Their comparative analysis revealed many gaps and inconsistencies among the species studied.

Their main complaint is that domestication syndrome has no standard definition that is applicable to all domesticated species. These hypotheses assume that the domestication syndrome exists, but with little supporting data, wrote the authors. The defining characteristics vary widely and have not been observed in most domesticated species. Many studies fail to distinguish traits that accompanied domestication from those only in modern breeds, and some traits are reported anecdotally without any accompanying frequencies or measurements.

The researchers devised a list of three essential criteria consistent with their interpretation of domestication syndrome, namely:

1. Onset: A trait must appear...in conjunction with the onset of selection for tameness.

2. Frequency: A trait must be significantly more common in the selected population.

3. Association: A trait must be associated with tameness in individuals, not just at the population level

When the researchers applied these criteria to domestication syndrome, they were unable to identify a single species for which all three criteria were met. The authors concluded that the Russian Farm-Fox Experiment is overstated as a model for understanding the effects of domestication, while adding that traditional conceptions of domestication need to be re-evaluated and re-defined.

Rather than focus on the domestication syndrome, we should instead consider how domesticated species have changed, and are still changing, in response to human-modified environments, wrote the authors. This effort will provide a robust framework to investigate the cultural and biological processes that underlie one of the most important evolutionary transitions.

In terms of whats happening to the animals, a lot of it might just be something we call genetic drift, which basically comes down to random chance, Karlsson told Gizmodo.

Perhaps unsurprisingly, the new opinion paper is not going over well with some biologists.

David MacHugh, a professor of functional genomics at University College Dublin, wasnt directly involved with the research but said he discussed Belyaevs experiment at length with Larson, a co-author of the paper, prior to publication. As MacHugh told Gizmodo in an email, he was convinced by the teams arguments regarding the Canadian provenance of the source population. As for the authors takedown of domestication syndrome, he was less persuaded.

It is important to note that as data accumulates from genome-scale functional and comparative analyses of domestic animals and their wild [ancestors], we should eventually have sufficient data to fully test the domestication syndrome hypothesis, said MacHugh.

He also said it should be possible to figure out if the biological basis of domestication syndrome is tied to genetic disruptions, or perturbations, that affect the development of various tissues derived from neural crest cells.

In other words, MacHugh believes the jury is still out on the neural crest hypothesis, but future genetics research will be able to finally settle the score. Whats more, he believes ongoing research into ancient DNA will allow paleogeneticists to better chronicle the history of domestication, pointing to a new study he co-authored on this exact subject.

Adam Wilkins, an evolutionary biologist from Humboldt University in Berlin, was less charitable, saying the opinion piece was deeply problematical.

As Wilkins told Gizmodo in an email, hes probably biased, since he was part of the team that put the term domestication syndrome on the map, with respect to mammals (the term had previously been used for plants), in reference to a 2014 paper he co-authored with biologists Richard Wrangham and Tecumseh Fitch.

The root of our disagreement lies, I think, in that we mean something different by syndrome than they do, Wilkins told Gizmodo. They seem to believe that something can only be called a syndrome if the affected individuals all display the exact same set of traits. Whereas we argue that if domestication is accompanied by a range of unselected traits, which might differ somewhat but often overlap, it counts as a syndrome.

Wilkins said he and his colleagues never claimed the existence of an identical set of traits across all domesticated mammals, which he says is implied in the new opinion piece.

Furthermore, under our neural crest cell hypothesiswhich the authors refer to briefly, twice, but do not explain or discusswhat you see is exactly what the hypothesis predicts, said Wilkins.

Specifically, that reductions in neural crest cellsthe result of different mutations in the large set of neural crest cell genesproduce a range of affected traits, he said, pointing to a recent Development and Evolution paper he wrote that provides more color to this claim.

Wilkins also took great exception to the authors assertion that the two fox populationsthe farm-fox population that Belyaev bred from and the foxes he producedwere essentially the same.

No! wrote Wilkins. This shows a lack of understanding of what an evolutionary process is. Belyaev clearly increased the frequencies of those mutant alleles [alternative forms of a gene] and brought them together and with that, he created a new population with distinctive properties. Now, that is evolution, as Belyaev recognized but [the authors] do not, he said.

This point is consistent with a 1999 review of the Belyaev experiment written by biologist Lyudmila Trut from the Institute of Cytology and Genetics of the Siberian Department of the Russian Academy of Sciences. In the paper, Trut describes the remarkable transformations seen in the foxes over a 40-year period, in an experiment that, at the time of her paper, involved some 45,000 foxes and somewhere between 30 and 35 generations.

The founding foxes were already tamer than their wild relatives, wrote Trut. Foxes had been farmed since the beginning of this century, so the earliest steps of domestication, capture, caging and isolation from other wild foxes had already left their marks on our foxes genes and behavior.

Despite this, the breeding program produced an array of concrete results, she wrote. The foxes are unusual animals, docile, eager to please and unmistakably domesticated. When tested in groups in an enclosure, pups compete for attention, snarling fiercely at one another as they seek the favor of their human handler.

Whats more, the unexpected physical changes werent seen until around the eighth to 10th selected generations, as Trut wrote:

The first ones we noted were changes in the foxes coat color, chiefly a loss of pigment in certain areas of the body, leading in some cases to a star-shaped pattern on the face similar to that seen in some breeds of dog. Next came traits such as floppy ears and rolled tails similar to those in some breeds of dog. After 15 to 20 generations we noted the appearance of foxes with shorter tails and legs and with underbites or overbites.

Wilkins raised several other issues with the new paper, including the authors failure to define domestication after claiming that Belyaevs experiment wasnt a true example of domestication. He also wasnt happy that they looked at just seven domesticated species instead of the 26 documented in the scientific literature.

If they had, they would have seen a lot more domestication-associated traits... including many that almost certainly were not deliberately selected by breeders, Wilkins told Gizmodo. They want to attribute all these changes to selection, however; at least, that is what they imply at the end [of the article].

Wilkins believes the array of anomalous traits seen in domesticated mammalswhether these traits are common or not across speciescannot be explained away so easily and that domestication syndrome best describes this biological phenomenon.

Deficiencies in our understanding of Belyaevs experiment notwithstanding, the authors of the opinion piece raise a very good pointdomestication syndrome as its understood today is not a fully formed concept. But that doesnt mean it doesnt exist.

Pleiotropy, in which a single gene influences multiple traits, is very much real, so it makes sense that you could get some unexpected surpriseslike floppy ears when you were only selecting for friendlinessby messing with a multifunctional gene.

Its not immediately obvious that many of the unexpected physical characteristics seen in domesticated animals are truly the result of selection (whether those traits were consciously bred into them or not) or genetic drift. Moving forward, scientists will need to better elucidate the underlying cause of each identified trait.

And if these accidental byproducts or side-effects can be indisputably identified as being the unanticipated consequence of domestication, then we have something that can only be called one thing: a syndrome.

More:
Famous Foxes Bred for Tameness Werent Actually Wild in the First Place, Claims Controversial New Paper - Gizmodo

Read More...

Iran Ready for Cooperation with Uzbekistan on New Technologies: Official – Iran Front Page – IFP News

December 13th, 2019 8:49 pm

In an address to a Thursday meeting of Uzbek and Iranian businesspeople and officials, held in Tashkent, Chairman of the International Interaction Centre of the Iranian Vice-Presidency for Science and Technology Mahdi Qalenoei hailed Uzbekistan as a friendly country and a major economic center near Iran.

Highlighting Irans efforts to boost trade ties with Uzbekistan in recent years, Qalenoei said Tehran and Tashkent can promote cooperation in the sphere of new technologies, considering the global technological advances, the regional and international environmental problems, the need for innovation in science, the necessity of optimizing energy use, the need for application of cognitive sciences, and the importance of increasing productivity and economic competitiveness.

He also expressed hope that academic cooperation between the two nations would accelerate the progress in new technologies such as nanotechnology, biotechnology, aerospace science, cognitive sciences, and new energies.

Today, more than 4,400 Iranian knowledge-based companies are offering technologies that sell in the domestic market and could also enter the international markets in case of joint investment in mass-production, he added.

According to the presidential official, the Iranian biopharmaceuticals are being exported to Russia, Turkey and other regional countries for the treatment of cancer and inflammatory diseases.

Qalenoei said Iranian pharmaceutical company CinnaGen has fulfilled the domestic need for biotech medicines, and is also capable of designing, constructing, equipping and launching pharmaceutical factories in the other countries.

The technologies developed by CinnaGen have been exported to Turkey, Syria, Southeast Asia, and Latin America, he added, unveiling plans for cooperation with the European countries.

The official then highlighted the advances made by Cell Tech Pharmed, saying the Iranian company has succeeded in curing four terminal illnesses with the use of stem cells and regenerative medicine.

The Iranian knowledge-based companies have also the technical know-how to manufacture advanced equipment such as surgical robots, linear particle accelerators, dosimetry apparatus, radio frequency systems, and cyclotrons used for medical diagnosis, he added.

Qalenoei also highlighted the Iranian knowledge-based companies progress in the production of livestock and poultry vaccines, antibiotics, hormones, and supplementary medicines.

Moreover, he added, the Iranian knowledge-based enterprises working on herbal medicine have developed a cure for chronic migraines, and have also invented herbal ointments for the treatment of bedsore, burns and diabetic ulcers.

There are more than 260 knowledge-based companies in Iran in the field of medical research and production of new pharmaceuticals, while around 200 other firms are engaged in innovative and research activities to develop medical equipment, said chairman of the International Interaction Centre of the Iranian Vice Presidency for Science and Technology.

Excerpt from:
Iran Ready for Cooperation with Uzbekistan on New Technologies: Official - Iran Front Page - IFP News

Read More...

Biobanking Equipment Market To Grow at a Stayed CAGR with Huge Profits by 2029 | Thermo Fisher Scientific Inc, BioLife Solutions Inc, Beckman Coulter…

December 13th, 2019 8:49 pm

New York City, NY: Dec 14, 2019 Published via (Wired Release) A recent business intelligence report out by Marketresearch.biz with the title Global Biobanking Equipment Market Extensive Study and Forecast 2019-2028 offers new insights and explanation on the market and help you to improve and enamel your business strategies. Biobanking Equipment market has abilities to rise as the most remarkable market globally as it has carried a crucial role in establishing a progressive impression on the universal economy.

The Global Biobanking Equipment Market report analysis comprises an extensive summary of the market that offers in-depth knowledge of various distinct segmentations. Biobanking Equipment Market Research Report gives a detailed analysis depend on the comprehensive research of the complete market, especially on questions that outskirt on the market size, growth landscape, potential opportunities, operation scenario, trend study, and competitive analysis of Biobanking Equipment Market. The data contains the company profile, Y-O-Y turnover, product type and services, income generation, which offers direction to businesses to take crucial steps.

The main aim of the Biobanking Equipment report is to assist the user to understand the market based on definition, distribution, industry potential, recent trends, and market challenges industry faces. Detailed researches were done while structuring the report. The Biobanking Equipment market readers will find this report very easy to understand and beneficial. The prospects and information presented in the report using Biobanking Equipment figures, bar-graphs, pie charts, and other visual representations. This enhances the Biobanking Equipment market pictorial representation and also get the benefit of getting the industry facts easily.

The Biobanking Equipment Market was valued at USD XX.XX Mn in 2020 and is projected to reach a value of USD XX.XX Mn by 2029 with an estimated CAGR value of X.X%.

Note: The above values marked with XX.XX is confidential information. To know the exact data and values, fill your information so that our sales team can get in touch with you.

For Better Understanding, Request A Free Pdf Sample Report Of Biobanking Equipment Market Here@ https://marketresearch.biz/report/biobanking-equipment-market/request-sample

Biobanking Equipment Market scope

A basic synopsis of the competitive landscape

A short summary of the market segmentation and sub-segments

An exhaustive breakdown of the regional expanse

A generic outlook of the competitive landscape

The report serves a thorough study of the competitive territory of this vertical.

The study includes details related to each industry participants particular market share, the area served, manufacturing data and more.

Information related to the producers product portfolio, product characteristics, and relevant product applications has been presented in the report.

The report includes companies profiles in association with the respect of the fact to their gross margins and price models

Biobanking Equipment delivers pinpoint study of distinct competition dynamics and place you ahead of Biobanking Equipment competitors such as BioCision, Thermo Fisher Scientific Inc, VWR International, Taylor-Wharton International LLC, BioLife Solutions Inc, Tecan Trading AG, Panasonic Biomedical Sales Europe BV, Beckman Coulter Inc, Promega Corporation, LLC, LLC and Tecan Group Ltd

A brief outline of the segmentation

The Biobanking Equipment Market report demonstrate the segmentation of this vertical with utmost precision.

Information with reference to Biobanking Equipment industry share assemble by each product segment, along with their market value, have been served in the report.

Data related to production growth has also been offered in the report.

With respect to the application spectrum, the analysis comprises details regarding market share, amassed by every application segment.

Further, the analysis emphasizes data related to the product consumption of each application, together with the growth rate to be estimated for by each application segment over the projected period.

Segmentation by product type: Equipment, Refrigerators and Freezers, Liquid Nitrogen Supply Tanks, Cryogenic Storage Systems, Media, Optimized Pre-Formulated Media, Non-Optimized Isotonic Formulation Media, Consumables, Others. Segmentation by sample type: Human Tissue and Tumor Cells, Bio-fluids, Stem Cells, Umbilical Cord, DNA/RNA. Segmentation by end user: Hospitals, Research Organizations, Blood Banks, Others (DNA Banks and Cell and Tissue Banks)

Any Query? Fill Free To Inquire Here: https://marketresearch.biz/report/biobanking-equipment-market/#inquiry

Biobanking Equipment Market: Regional analysis includes:

Asia-Pacific (Japan, Philippines, Korea, Vietnam, China, Malaysia, Thailand, India, Indonesia, and Australia)

Europe (Russia UK, Italy, Turkey, Germany, France, etc.)

North America (United States, Mexico, and Canada.)

South America (Brazil, Argentina, Chile etc.)

The Middle East and Africa (GCC Countries, Dubai, Iran and Egypt)

An all-inclusive portfolio of the geographical terrain

The research report comprehensively segments the geographical landscape of this industry. As per the report, the Biobanking Equipment Market has established its appearance across the distincr regions such as United States, Japan, China, Europe, Southeast Asia & India.

The report consist insights relating to the industry share obtain by each region. Moreover, data regarding growth opportunities for the Biobanking Equipment Market across every comprehensive region is provided within the report.

The predicted growth rate recorded by each region over the forecast years has been precisely mention within the research report.

Some of the Major Highlights of TOC covers:

Biobanking Equipment Market Regional Analysis

Biobanking Equipment Production by Regions

Worldwide Production by Regions

Biobanking Equipment Market Global Revenue by Regions

Consumption by Regions

Biobanking Equipment Market Segmentation Study (by Type)

Worldwide Biobanking Equipment Production by Type

Global Revenue by Type

Global Share by Type

Biobanking Equipment Market Price by Type

Biobanking Equipment Market Segmentation Study (by Application)

Global Biobanking Equipment Consumption by Application

Global Market Share by Application

Global Revenue by Application

Biobanking Equipment Market Price by Application

Biobanking Equipment Major Manufacturers Study

Production Sites and Region Served

Product Introduction, Application and Stipulation

Biobanking Equipment Production, Ex-factory Price, Revenue, and Gross Margin

Vital Business and Markets Served

Browse More Insight Of This Biobanking Equipment Market Research Report Enabled with Respective Tables and Figures at: https://marketresearch.biz/report/biobanking-equipment-market/

Thanks for going through this article, you can also get separate chapter wise section or region wise section report. Also, if you have any special/particular requirements, please let us know and we will serve you the report accordingly.

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel: + 1-347-826-1876

Email ID: inquiry@marketresearch.biz

Website: https://marketresearch.biz/

Read the original:
Biobanking Equipment Market To Grow at a Stayed CAGR with Huge Profits by 2029 | Thermo Fisher Scientific Inc, BioLife Solutions Inc, Beckman Coulter...

Read More...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market share, size, opportunities, producers, growth factors by 2026 – Health Opinion

December 13th, 2019 8:49 pm

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report 2018-2026includes a comprehensive analysis of the present Market. The report starts with the basic Autologous Stem Cell and Non-Stem Cell Based Therapies industry overview and then goes into each and every detail.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Autologous Stem Cell and Non-Stem Cell Based Therapies also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Description:

Autologous stem-cell transplantation (also known as autogeneic, autogenic, or autogenous stem-cell transplantation or auto-SCT) is the autologous transplantation of stem cellswhich is, transplantation in which the undifferentiated cells or stem cells (cells from which other types of cells develop) are taken from a person, accumulated, and given back to the same person later. Even though it is most often executed by means of hematopoietic stem cells (antecedent of cells that forms blood) in hematopoietic stem cell transplantation, in some cases cardiac cells are used productively to fix the damages due to heart attacks. Stem cell transplantation can be of two types Autologous stem-cell transplantation and allogenic stem cell transplantation. In the later, the recipient and the donor of stem cells are dissimilar people. In a good number of allogeneic transplants, the stem cells are taken from a donor whose cell type matches closely with the patients cell type.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market competition by top manufacturers/players, with Autologous Stem Cell and Non-Stem Cell Based Therapies sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including: NeoStem, Inc., Aastrom Biosciences, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.

Get Free Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/523

Important Features that are under offer & key highlights of the report:

What all regional segmentation covered? Can the specific country of interest be added?Currently, the research report gives special attention and focus on the following regions:North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

What all companies are currently profiled in the report?The report Contain the Major Key Players currently profiled in this market.** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

Can we add or profiled new company as per our need?Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by the research team depending upon the difficulty of the survey.** Data availability will be confirmed by research in case of a privately held company. Up to 3 players can be added at no added cost.

Can the inclusion of additional Segmentation / Market breakdown is possible?Yes, the inclusion of additional segmentation / Market breakdown is possible to subject to data availability and difficulty of the survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.** Depending upon the requirement the deliverable time and quote will vary.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/523

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics in the world mainly, the worldwide 2018-2026 Autologous Stem Cell and Non-Stem Cell Based Therapies Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Region Segmentation:

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Further in the report, the Autologous Stem Cell and Non-Stem Cell Based Therapies market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Autologous Stem Cell and Non-Stem Cell Based Therapies industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Quick Buy This Premium Report From Here: https://www.coherentmarketinsights.com/insight/buy-now/523

In this study, the years considered to estimate the market size of 2018-2026 Autologous Stem Cell and Non-Stem Cell Based Therapies Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

See original here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market share, size, opportunities, producers, growth factors by 2026 - Health Opinion

Read More...

Why you need to know about telomeres – MultiBriefs Exclusive

December 13th, 2019 8:47 pm

Many of us know that long-term stress can affect our health, but did you know that it can also impact aging and longevity?

Welcome to the world of telomeres.

According to an article by The American Institute of Stress, Telomeres are little caps at the end of chromosomes that prevent loss or injury to genetic information during cell division. Each time a cell divides, part of the telomere is lost and it becomes shorter. When a telomere eventually disappears because of repeated cell divisions, chromosomal damage prevents the cell from accurately reproducing itself. This shortening and eventual erosion of telomeres are prevented or reduced by telomerase, an enzyme in cells that preserves their length. Many believe that telomere destruction and reconstruction is related to the balance between aging and cancer and explains why cancer is more common in the elderly.

In addition to cancer, shorter telomeres have also recently been associated with a whole host of other diseases, including cardiovascular disease, osteoporosis and diabetes.

I first learned about telomeres in 2016, when I worked for a human potential physician that specialized in optimizing health through lifestyle changes. He was one of the first physicians in the country that built his practice around the awareness that lifestyle and behaviors impact ones genetics.

My former boss told me that his high stress levels during his medical training had severely shortened his telomeres and that he was working hard to reverse that by optimizing his own health as well as that of his patients. Not only was I excited to learn about this, but it was also inspiring to learn that there were ways to undo previous damage.

The foundation of his approach was based on measuring stress levels and then teaching people through biofeedback to regulate breathing and heart rate. He then added personalized recommendations based on individual genetics for additional stress-reducing and health-enhancing lifestyle changes, including diet, exercise, meditation, sound therapy, acupuncture, etc.

My former boss was in good company. A number of researchers and physicians were studying how lifestyle changes could reverse telomere shortening. One of the first studies was published in 2013 by Dean Ornish, a physician, best-selling author and head of the Preventative Medicine Research Institute at the University of California in San Francisco.

There is now a lot more information available versus 2013. A best-selling book, The Telomere Effect: A Revolutionary Approach to Living Younger, Healthier, Longer, was published in 2017 and was co-authored by Dr. Elizabeth Blackburn, who originally discovered the role of telomeres on aging, and psychologist Dr. Elissa Epel. Heres a wonderful passage from the book:

To an extent that has surprised us and the rest of the scientific community, telomeres do not simply carry out the commands issued by your genetic code. Your telomeres, it turns out, are listening to you. They absorb the instructions you give them. The way you live can, in effect, tell your telomeres to speed up the process of cellular aging. But it can also do the opposite.

The book is full of helpful information. For optimal health, the authors recommend a plant-based diet of nutrient-rich foods that are high in antioxidants. In addition, they also recommend focus, mindfulness and meditation as stated here:

One study has found that people who tend to focus their minds more on what they are currently doing have longer telomeres than people whose minds tend to wander more. Other studies find that taking a class that offers training in mindfulness or meditation is linked to improved telomere maintenance.

The benefits of making healthy lifestyle choices are well-known. However, knowing that you can greatly increase your chances of living longer and becoming healthier in the process because youre changing your genetic expression is pretty amazing.

Since were almost at the end of 2019 and about to begin a new year, this might be a perfect time to implement some new lifestyle choices, especially now that you know that your telomeres are listening.

See more here:
Why you need to know about telomeres - MultiBriefs Exclusive

Read More...

Cannadabis: tissue culture and the future of cannabis cultivation – Health Europa

December 13th, 2019 8:47 pm

Cannadabis Medical INC they intend to create a healthier and more consciously aware environment for the cannabis industry, and its participants, to thrive in.

Did you know that Cannadabis are Partners with us? Discover their featured Partner Page about a healthier, environmentally conscious cannabis industry.

The company is a family run company that was founded in Humboldt, Saskatchewan.

Founders, Alexander Calkins, BSc and Markus Li, P.Chem, MBA, are personally and emotionally invested in the science of cannabis. They each have family members that are dealing with incurable ailments, complications of which can often become fatal.

In the search for natural products that will improve the quality and longevity of life, the founders began working with cannabis. While there is no likelihood of a cure, the symptom management has been very positive for their family members. After witnessing the improvements, Cannadabis founders Calkins and Li, have dedicated themselves to furthering the medical cannabis movement.

Calkins and Li both have backgrounds in technical science and business. They are experienced cultivators and have a strong understanding of energy systems (practically essential for a power-hungry industry), process automation, and large-scale development.

Their familiarity with multi-industry supply chains has leveraged them into a cannabis development that is simultaneously high-tech, old school, and simple.

Through observation of established global industries, Cannadabis is building a multi-faceted business model based on sustainable practices, a strong genetics portfolio, disruptive technologies, hyper-specialisation, and holistic production.

Driven by a passion to help others in need, Calkins and Li took it upon themselves to bring their methods and expertise to the cannabis world. They recognise and praise the patient independence that medical cannabis can provide.

While they champion the practice of homegrown medicine, they have obligated themselves to providing the safest and highest quality medical products to those who are unable to grow for themselves.

Once Cannadabis has perfected its organic growing system, they will build and operate all future cultivation sites according to (EU) GMP and ISO:9001 2015 standards. By adopting these standards, Cannadabis will have the ability to share their cultivated passion with the world.

To meet the sanitary requirements of GMP and processing limitations of an organic certification, Cannadabis will be using a combination of reactive oxygen, electrolysed water, and radio frequency pasteurisation technologies.

Being a medically focused company, Cannadabis recognises that medical consumers have turned to cannabis because they are looking for natural remedies and are becoming increasingly weary of synthetic medicines.

For Cannadabis, producing medical cannabis using anything other than organic methods would transgress the fundamental sentiment that drives the global, medical movement. That is why Cannadabis is committed to attaining internationally recognised organic certifications on expanded production.

The companys flagship facility is intended to be an R&D focused proving ground for state-of-the-art organic cultivation methods. Cannadabis currently uses an inhouse blended soil, made only with organic ingredients. Their living soil has the benefit of creating terpene dense medicine, reducing cost, and simplifying processes.

With all the nutrients available in the soil, the plants require only water from transplant to harvest. Additionally, the growing medium and all organic waste can be recycled through vermicomposting, further reducing long term costs and needless waste.

Cannadabis will adopt various technologies to reduce energy demand and environmental impact. In addition to using LEDs and solar panels, Cannadabis will use combined heat and power (CHP) (or cooling combined heat power (CCHP)) at their cultivation facilities. CHP units burn natural gas to generate power and the waste heat is used to heat water and the workspace. CHPs are quickly becoming popular for reducing carbon emissions. In certain applications, CHPs reduce carbon emissions by 30-40%, compared to when power is taken from the grid.

Cannadabis will also divert the combustion CO2 into the growing space. CO2 supplementing supercharges growth naturally, increasing yield by 30-60%, and further reducing the carbon emissions from power generation. In the future, expanded cultivations may integrate pyrolysis of waste biomass, which will supply power and nutrient dense biochar to the living soil.

Cannadabis is aspiring to build a unique indoor growing system that uses a combination of solar power, water recycling, CHP (CCHP), pyrolysis, CO2 supplementation and vermicompost to create a no waste, carbon neutral, minimal input, self-regenerating nutrient, off grid, medical grade, organic, indoor cultivation.

Calkins and Li hope to validate the system and then apply the techniques to food cultivation; this type of system could revolutionise the food production in remote locations, like the northern territories, Alaska and would deliver food supply independence to small communities or reservations. Where biomass is abundant, this system would produce all year, requires only labour as inputs, self-generate power off-grid, and would also be carbon negative over extended time frames.

On their path to improving growing efficiency, Cannadabis has developed proprietary tissue culture methods specifically for cannabis. These methods are based upon the decades old horticultural practice that has been essential for the sterile propagation of ornamental and food cultivars; non seed propagation.

Developing an inhouse tissue culture system has the following benefits:1

Tissue culture revitalises cultivars and produces more vigorous plants Regeneration from meristem rids systemic disease; Propagation is significantly more efficient; Starting with 100 traditional cuttings; able to produce 70,000 annual clones; Start with 200 tissue culture vials; produce 2 million annual clones; Uses 1/10 the space of traditional cloning; Per square foot, tissue culturing is >100x more efficient; and Two million annual clones could be produced in less than 3000 square feet.

1000 mother cultivars could be stored inside a refrigerator with no care or maintenance for months, sometimes over a year; and Pest invasion would not affect mother cultures (many cultivators without tissue culture have lost their entire genetic inventory to viruses and fungi).

Cannadabis will be sharing its tissue culture methods with industry members who want to stay one step ahead of pests and systemic disease. Following more development, they will also be making their organic formulations available.

Having collected and grown a large variety of cultivars, both through seed and clone, the Cannadabis founders have noticed a distinct lack of quality in the genetics market. Over time, most of the popular cultivars of the world have been slowly degraded by deleterious breeding practices like selfing (feminising), backcrossing, and poor mother plant maintenance which promotes genetic drift.

The current genetics market is rife with breeders that take prized clones and spray them with colloidal silver to produce feminised seed, or they are crossed onto their own cultivars and backcrossed until stable seed is produced.

While these name sake creations may capture some of the qualities of the original strain, like trichome density or terpene profile, the progeny will lack the genetic diversity needed to produce healthy plants. Often, these weakened strains have reduced yield, potency, and pest resistance. In response to this, Cannadabis has focused on breeding their own high yield, high potency, flavour dense strains for commercial production.

The Cannadabis team is eager to unveil their propriety strains to the domestic and international medical markets. Over the past few years, the founders have started breeding their own cultivars. Currently, the team has focused on a selection of stabilised true breeds (landrace or F5+) for creating original F1 breeds.

Where the F1 generation is created by breeding male and female plants that are distinctly unique from each other; traditional F1s are created by crossing landrace indicas with landrace sativas.

These crosses need to be done with highly stable and uniquely different parents to produce a true F1 progeny that has abundant hybrid vigour. A plant with true hybrid vigour will typically have higher potency, increased pest resistance, and a higher yield than both parent plants; on average yield can be as high as 20% more than either parent.

Due to the nature of the F1 progeny, very few breeders release true F1 seeds. If highly stable progenitors are not used, the seedstock will be incredibly variable, which is unfavourable for consumers, who typically want consistency in their seed. However, as commercial cultivators, Cannadabis believes that F1 hybrids are essential for producing at large scale. The breeding and phenotyping can be a long and arduous process, the fruits of labour are not without commercial benefit.

Building upon the tissue culture and breeding practices, Cannadabis is quickly developing polyploidisation methods for creating ultra-premium cultivars. Polyploidisation is another common horticultural practice that Cannadabis expects to apply to their cannabis breeding projects.

Polyploidisation is a naturally occurring mechanism where the chromosomes of the plant cells become doubled within the same nucleus. This mechanism has played a significant role in speciation of crops, occurring frequently in nature, usually due to stress response.

In the 100 years since scientists discovered polyploidy, there has been rapid development of polyploid breeds. It is estimated that up to 80% of all flowering plants have polyploid varieties.2 Common polyploid cultivars includes wheat, coffee, banana, strawberry, potato, etc.

Polyploidy has been researched since the early 1900s. Scientists first used heat and electrical stress to induce those mechanisms. Today polyploidy is more commonly, and consistently, induced with radiation and stressing chemicals. Interestingly, induced polyploidy is explicitly exempt by most organic certification bodies. These types of breeds typically do not fall under genetically modified until foreign, non-similar species, DNA is introduced to the plant cell.

These polyploids are called autopolyploid (same species), and plants made with dissimilar species are called allopolyploids. Cannadabis will also be exploring organic permitted cell fusion; this would allow breeding with two male plants, or two female plants.

In the past, the following horticulture benefits have been derived from polyploidy and cell fusion, which Cannadabis hopes to similarly apply to the cannabis plant:3

The same can apply to cannabis. Strains can be developed that would never seed regardless of direct pollination; massive utility available to outdoor or indoor cultivators with seeding problems.

Cannadabis hopes to release their first polyploid strains in late 2020.

Cannadabis has begun manufacturing premade tissue culture mediums and are currently distributing them to Western Canadian horticulture stores and Amazon Marketplace; the mediums are a standard blend that works on 95%+ of the founders cultivars. The founders tissue culture experience is being provided to the public in both consumer and commercial grade products.

The introductory products show unfamiliar users how to do tissue culture at home, using proven methods that do not require expensive laboratory equipment. Besides what comes in the starter kit, the everyday home grower will usually have all the remaining materials at home. Commercial format mediums are intended for growers that want the best value and space savings.

Cultivators of any background can find information or help on tissue culture through the Cannadabis homepage. They are posting helpful videos and literature on cannabis tissue culture and hope to share the benefits with every grower. All horticulturalists, cannabis or not, can benefit from having their cloning area be 100x more efficient, through stackable containers. Furthermore, their mother plants can easily be maintained with minimal care. 100-1000 mother cultures can be stored within a refrigerator for 4-8 months, no adding nutrient or water. For larger cultivators, Cannadabis provides PGR matrices to more easily troubleshoot difficult cultivars. They also will custom blend and sterilise mediums to customer preference.

Cannadabis has begun developing an automated cell culture process for mass propagation of cultivars. The economies of scale of which are expected to change the supply chain of the entire cannabis industry. Automated cell culturing will provide starting materials to the industry at a fraction of the cost of inhouse cloning. Clones produced through cell culturing will also have the benefit of being totally sterile and free from disease.

Cannadabis has been offered an NRC-IRAP grant for initial developments of the process and are in early negotiations with a Canadian cannabis company to commercialise. The founders are expecting to file patents, mid 2020, and begin construction of a commercial scale process by mid-2021. Cannadabis anticipates that a 5000 sq ft facility will produce 5+ million clones annually, with minimal labour.

The project is looking to possibly incorporate the production of artificial seeds, which would simplify transportation and ease of storage for cultivators. They will also be developing cryogenic preservation methods. Cultivators around the world are encouraged to reach out to Cannadabis if they are looking to simplify their process, access cell culture benefits, and maximise growing space.

Working with Cannadabis cultured clones will be the most affordable, safe, and efficient way of acquiring starting material. Their services would include meristem culturing to remove systemic disease, and long-term storage of genetic inventory. Partners who end up with a pest could rest easy knowing their mother cultures will be perfectly preserved in tissue culture, and fifty thousand clones for the next crop are still on the way.

Cannadabis Medical and Delta 9 Cannabis have teamed up to provide an affordable, turnkey, tissue culture laboratory, complete with operating procedures, equipment, and cannabis medium recipes.

The two companies have co developed this system for their own commercial use and have recently made the system available for other cultivators. Both companies have recognised that the cannabis industry is still reliant on black market methods of propagation, and as a result, there have been countless incidents of crop and genetic loss in the legal industry; many of the stories circulating are understandably refuted by the companies experiencing such loss.

Rather than ignore the inevitable pest problems, the two companies are going toe to toe with mother nature, developing half century old technology and making it specifically for cannabis. Hopefully delivering the same modicum of control to the rest of the industry; cultivators slow to develop tissue culture science may soon find their genetics and crop totally destroyed by a single, often microscopic pest. On a commercial scale, these pests become essentially impossible to remove without the use of tissue culture.

With feet rooted in genuine care, Cannadabis and Delta 9 are prepared and excited to deliver a tissue culturing system to the global cannabis industry. They recognise the value and utility available to growers, and they also recognise that learning tissue culturing can feel out of reach for cultivators with no prior knowledge, or excess funding to hire an inhouse specialist.

Instead of missing out or paying specialists, cultivators can rely on Cannadabis and Delta 9 to deliver a ready to use laboratory, the development of which was based on maximising value for the growers.

The laboratory comes with only bare essentials and extensive, yet simple, operating procedures. Training materials will detail cannabis specific mediums, sanitation protocols, along with troubleshooting methods for finicky cultivars; an inexperienced grower will be comfortably blending and using mediums on the same day of commissioning. The whole system, equipment and all, will be much more affordable than hiring a tissue culture specialist.

Over the next three years, Cannadabis will be working to establish an expanded cultivation with the hope of supplying medical, organic, indoor grown cannabis to domestic and international markets.

They will also pioneer an original cell culture process that expects to be the most affordable source for starting materials in the world; Cannadabis is especially excited to deliver their polyploid cultivars as starting materials to industry members.

Cannadabis would like to offer an open invitation to all scientists, entrepreneurs, and industry professionals for collaboration. We are actively seeking partners who share a similar vision for the cannabis industry. Any professionals who are driven by a sense of genuine care and have a passion for cannabis medicine are encouraged to reach out.

References

1 hempindustrydaily.com/hemp-cultivators-tissue-culture-increase-propagation-preserve-genetics/2 Meyers, L. A., and Levin, D. A. (2006). On the abundance of polyploids in flowering plants. Evolution 60, 11981206. doi: 10.1111/j.0014 3820.2006.tb01198.x3 http://www.slideshare.net/ranganihennayaka/plant-polyploids4 http://www.frontiersin.org/articles/10.3389/fpls.2019.00476/full5 plantbreeding.coe.uga.edu/index.php?title=5._Polyploidy

Alexander CalkinsCEOCANNADABIS Medical INC+1 306 552 4242alexander@cannadabismedical.caTweet @cannadabiscannadabismedical.ca

This article will appear in the first issue ofMedical Cannabis Networkwhich will be out in January.Clickhereto subscribe.

Follow this link:
Cannadabis: tissue culture and the future of cannabis cultivation - Health Europa

Read More...

Keeping Your Childs Baby Teeth Could Save Their Life In The Future – BabyGaga

December 13th, 2019 8:46 pm

Medical technology now tells us that when kids'baby teeth are kept safe,valuable cells are stored inside that can lead to possibly life-changing research work with stem cells down the road.

Remember when you were a kid and you couldn't wait until that pesky loose tooth finally wiggled itself free so that you could put it under your pillow and wait for a visit from the mysterious Tooth Fairy? A gift in exchange for an old tooth seemed like a pretty sweet deal at age 7 but now, according to medical professionals, those fallen baby teeth are the true gift; worth their weight in stem cell gold.

RELATED: 10 UNPLEASANT TRUTHS ABOUT BABY TEETHING (AND 10 THINGS MOM CAN ACTUALLY DO)

According to Small Joys, baby teeth are made nearly entirely of cells and these dental cells are going to be in big demand in the future. The reason for this is that our bodies are made completely of cells, divided in three categories of functionalities. Dental cells belong into the stem cell category and because these are caught at the early stage of development in your child's life, they just might be able to save your child's life down the road should the occasion ever arise.

For such an amazing task, you might be thinking how much is the storage going to cost at the expensive cryogenic laboratory that you're going to have to find to keep your child's baby teeth at? But no worries there because Small Joys says that according to medical technology professionals, the dental cells are already perfect preserved in their own little chambers. All you need to do is provide them with a nice, dry, safe and clean environment. This can be something as simple as a little BPA-free box with a snap lid.

NEXT:METALS IN BABY TEETH MAY HELP REVEAL THE CAUSES OF AUTISM, ADHD, STUDY SAYS

Be sure to mark the outside with the contents such as your child's complete name, the date they lost their tooth, the age they lost the tooth at, and maybe even the location of the tooth if you can. You can easily find a dental chart online. If you're feeling fancy, there are even some little cases made just for the occasion that comes with spaces for each tooth! Can't go wrong there.

In the end, hanging on to baby teeth is important to help doctors and scientists help make great strides in the world of stem cell research and breakthroughs with major diseases. Plus you've got to admit that it's also kind of cute to save for the memories, too!

Kenya Moore Of "RHOA" Shares Video Of 13-Month-Old Daughter Taking Her First Steps

Tags:health

Link:
Keeping Your Childs Baby Teeth Could Save Their Life In The Future - BabyGaga

Read More...

2020 Legislative Session A Sampling of Health Related Bills Filed – JD Supra

December 13th, 2019 8:46 pm

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

See the original post here:
2020 Legislative Session A Sampling of Health Related Bills Filed - JD Supra

Read More...

HIV Vaccine Researchers Unveil New Strategy In Fight Against HIV : Goats and Soda – NPR

December 12th, 2019 4:55 pm

An image of HIV from a scanning electron microscope. A vaccine project is in very early stages, but it's sparking interest among scientists in the field.

Ever since the AIDS epidemic erupted nearly 40 years ago, researchers have tried to make a vaccine.

The efforts typically end up like this: "Failure Of Latest HIV Vaccine Test: A 'Huge Disappointment.' "

Now researchers have come up with a new blueprint.

The method behind their potential vaccine mimics a rare process detected in the immune systems of some people with HIV a process the reduces the amount of virus in the body.

The team from Duke and Harvard behind the work, which appears this month in the journal Science, says there is still a long road ahead before an actual vaccine is ready for large-scale field trials. But scientists in the field are more optimistic than they've been for some time.

"For the first 20 years after the virus was discovered, the field tried to make a vaccine using the techniques that all the successful measles, mumps, rubella, polio vaccines had been made with in the past. And none of those worked," says Barton Haynes, director of the Duke Human Vaccine Institute and a lead author of the new research. But with a virus that's constantly mutating to evade the immune system, the antibodies generated weren't strong enough to fight it off.

But in about 20% of people who get infected with HIV, their immune systems will make special proteins called "broadly neutralizing antibodies." These antibodies live up to their name by wiping out many different strains of HIV by attacking the parts of the virus that stay constant, even as it evolves.

These proteins tend to develop several years after infection and can stop the virus from replicating for a while although they don't cure people of HIV because there's always a reservoir of the virus hiding out in cells where antibodies can't reach them.

But earlier tests in animals showed a powerful way forward: When they were infused with these antibodies before exposure to HIV, infections were prevented.

But there was a problem: The protection was short-lived.

In the new research, Haynes and his colleagues use computer modeling and lab testing on mice and monkeys to figure out how to train an immune system that's not been compromised by HIV to create these special antibodies and then continue to make new, stronger generations.

"We show a new way to design the HIV vaccine to guide the broadly neutralizing antibodies to go down paths they rarely go down on their own," Haynes says. The vaccine would also train the immune system to make these antibodies in months instead of the natural timetable of years after human exposure to the virus.

The approach looks promising to Rowena Johnston, research director at the nonprofit Foundation for AIDS Research, or amfAR, who was not involved with the study. "Nature is the best engineer when it comes to working out what our immune system should do," she says.

A vaccine based on these antibodies also has the potential to be far more effective than others in development. There currently are three HIV vaccine candidates in the final stages of human testing, and they'll be considered successful if they protect just half the exposed population from getting HIV. The benefit of this new method is that because it's introducing more powerful antibodies than the other vaccine candidates, it could lead to a vaccine that is 80-90% effective, says Dr. John Mascola, director of the Vaccine Research Center at the National Institutes of Health (NIH), who was not involved with the study.

Haynes' team is a third of the way through developing several of these antibodies, and they'll need more types to make an effective vaccine, something they say they're confident they'll be able to do.

Mascola estimates that it will take at least another five years for an HIV vaccine based on this research to get to large-scale clinical trials.

Continue reading here:
HIV Vaccine Researchers Unveil New Strategy In Fight Against HIV : Goats and Soda - NPR

Read More...

Study: Probiotic modulation of the immune system relieves hay fever symptoms – NutraIngredients.com

December 12th, 2019 4:55 pm

Griffith's research team at the Menzies Health Institute QLD carried out theanalysis, whichexamined changes in systemic and mucosal immune gene expression in a subgroup of individuals, classified as either responders or non-responders based on improvement of AR symptoms in response to the probiotic supplement.

The report notes that previous evidence suggesting that probiotics can produce clinically meaningful improvements in rhinitis symptoms is mixedand may be confounded by issues related to study design.

The assessment, published in the journalGenes,established criteria of a beneficial change in the mini-rhinoconjunctivitis quality of life questionnaire (mRQLQ).Systemic and mucosal immune gene expression was assessed using nCounter PanCancer Immune Profiling (Nanostring Technologies, Seattle, WA, USA) kit on blood samples and a nasal lysate.

There were 414 immune genes in the blood and 312 immune genes in the mucosal samples expressed above the background threshold.

Unsupervised hierarchical clustering of immune genes separated responders from non-responders in blood and mucosal samples at baseline and after supplementation, with key T-cell immune genes differentially expressed between the groups.

The report states: "Striking differences in biological processes and pathways were evident in nasal mucosa but not blood in responders compared to non-responders.

"These findings support the use of network approaches to understand probiotic-induced changes to the immune system."

Dr. Pete Smith of Queensland Allergy Services and a member of the study team said, "our study may allow us to personalise probiotic treatment for individuals with seasonal allergic rhinitis."

Dr. Nic West of Griffith University added that the results will allow researchers to conduct targeted research to find strategies people can use during the pollen season.

Source: Genes

West et al.

Digital Immune Gene Expression Profiling Discriminates Allergic Rhinitis Responders from Non-Responders to Probiotic Supplementation

DOI: 10.3390/genes10110889

Read more:
Study: Probiotic modulation of the immune system relieves hay fever symptoms - NutraIngredients.com

Read More...

This 5 spice syrup can boost your immune system this winter! – Times of India

December 12th, 2019 4:55 pm

As the chilly weather sets in, viruses and germs start operating in full swing and everybody around you seem to be catching the same flu or fever! While it is impossible to actually escape from the germs in the air (or stay away from sick people), what you can actually do is strengthen your immune system, naturally, without added supplements! Confused? Here's an easy remedy to save yourself and stay protected from diseases and enjoy the winter season.Here's whyOur immune system is charged with disease-fighting antioxidants, white blood cells, and several antibodies. However, if you have a weak immune system, you are more susceptible to catching diseases or fall sick more often. Therefore, people are often advised to include certain foods in their diet to get healthy naturally and build strong immunity. One such concoction, in particular, promises super quick results and can even act as a natural protectant against cold and fever.

How to prepare itTo make this simple winter immunity boosting syrup, you will need:

-Horseradish root (1 root)-Apple cider vinegar diluted in water (1 cup)-Turmeric (1 tablespoon)-Peppercorns (5-6 or handful)-Fennel seeds (1 tablespoon)-Clove (1 peice)-Ginger ( half a root)-Garlic (a few cloves)-Orange peel (1/2 cup)-Dried elderberries (1 tablespoon)-Honey (to soften the taste)

This immune-boosting syrup can be your go-to rescue drink whenever a cold or a flu symptom strikes you. An infusion drink of sorts, the syrup contains the goodness of herbs and potent natural medicines in diluted Apple Cider Vinegar, which again, is a super healthy drink. Together, they make an 'oxymel', a traditional honey-acid balancing mixture that can fight several germs at once.

To make this drink, first, start by straining all of the spices and herbs together in a pan filled with water (2 glasses). Allow it to simmer down completely, so as the consistency sort of thickens up. Once down, allow this prepared concoction to cool down completely, before adding it to the diluted apple cider vinegar. Mix thoroughly and allow it to settle well.

Read the rest here:
This 5 spice syrup can boost your immune system this winter! - Times of India

Read More...

The smart-dumb question, a key to writing about and understanding immunology – The Mix

December 12th, 2019 4:55 pm

The UAB freshman immunology honors seminar recently held a Q&A with Pulitzer Prize-winning newspaper reporter Matt Richtel.

The human immune system makes my head explode, Pulitzer Prize-winning journalist Matt Richtel recently told a University of Alabama at Birmingham freshman seminar on immunology. This is by far the hardest subject I have ever had to explore.

Richtel, a longtime New York Times reporter, was explaining why he wrote his general interest book An Elegant Defense The Extraordinary New Science of the Immune System, which the class was reading.

Richtels curiosity began when his boyhood buddy Jason Greenstein, the best kind of jock, got cancer in his 40s.

He had 15 pounds of cancer, went into hospice and was supposed to die, Richtel said through a video link with the UAB Honors College freshman seminar. However, when Greenstein who had nine toes in the grave got experimental immunotherapy, the cancer disappeared, though Greenstein later died. I didnt understand, Richtel said. What is this thing called the immune system, that they can tinker with to keep us alive?

Indeed, what is this thing, which is so complex and important in human health, development and disease? The UAB seminar freshmen are just beginning to scratch its surface.

In many ways, immunology is as challenging a major as neuroscience, another undergraduate major found in the UAB College of Arts and Sciences and at many other colleges.

Both the nervous system and the immune system are composed of a widespread network of organs, tissues, cells and soluble mediators that work together. Both systems interface with every organ in the body, as well as each other. Each plays critical roles in health and disease, and both require years of study for a student to grasp how the system works, and to tread a landslide of nitty-gritty mechanistic interactions that regulate normal function, or that misfire to cause disease, dysfunction and, sometimes, death.

Yet the two majors have a difference. Neuroscience is far more obvious. Each of us knows we have a brain. We daily experience five senses that report the world around us and convey pleasure or pain. Many of us have relatives or older friends who suffer the visible signs of neurodegenerative disease.

Immunology lacks this focus. Where or how does the immune system operate? What are its components? For most of us, the immune system is a vast, foggy landscape where many important things happen beneath our notice.

These differences explain, perhaps, why the number of neuroscience undergraduate majors has boomed in the past three decades, while in-depth immunology undergraduate majors still remain few. One of the few is UABs major, begun in 2017.

Three UAB faculty assert the need to revolutionize undergraduate immunology education in a Frontiers in Immunology paper.

The UAB immunology joint-health program in the UAB Department of Biology and Department of Microbiology is a four-year curriculum. After the freshman UAB honors seminar, full-semester courses include current topics in immunology, the innate immune system, the adaptive immune system, the microbial pathogen-immune system interaction, and immunologically mediated diseases.

The education is wide-ranging, and students also work in laboratories, readying themselves for careers in the health professions or research.

Immunology, by nature, is interdisciplinary, said Lou Justement, Ph.D., the teacher, along with Heather Bruns, Ph.D., of the honors seminar. Both are microbiology faculty in the UAB School of Medicine. It requires a knowledge of cellular and molecular biology, genetics, biochemistry, physiology, and anatomy. Freshmen are introduced to medically related conceptual frameworks that continue through the four-year curriculum how immunology relates to vaccines, emerging infectious diseases, autoimmunity, allergy, transplantation, cancer and immunotherapy. Students learn how the immune system is relevant to health and disease.

Richtel took a different approach. Rather than write an immunology textbook, he put faces on the role of immunology in health and disease. Parts of An Elegant Defense tell the stories of Jason, Bob, Linda and Merredith, and the burdens they faced Hodgkins lymphoma, HIV infection, rheumatoid arthritis and lupus. Richtel also relates surprising twists and turns for basic researchers who studied the immune system. Its a story, he writes at one point, that begins with a bird, a dog and a starfish.

During the video Q&A with students, Richtel wore a UAB T-shirt. Most of the UAB students asked how he reported and wrote the book. One of the hardest things to do when writing is to find your framework that will pay off the reader as you promised, he said.

And Richtel asked questions right back, offering guide stones of advice for the students:

UAB freshman Chandni Modi was one of the enthusiastic participants in the Q&A with Richtel. Afterward, the Indian Springs School graduate said, Honestly, at the beginning of my high school senior year, UAB wasnt one of my top choices. However, after I started comparing my options, UAB was the only school that offered immunology as a major, and UAB offers so many ways to get involved in research.

Also, she said, I appreciated how diverse the university students and faculty are.

Go here to read the rest:
The smart-dumb question, a key to writing about and understanding immunology - The Mix

Read More...

Page 794«..1020..793794795796..800810..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick